Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kura OncologyKURA -4.63%28 Gross Margin % is 98.57% as of Mar. 2026, which is 1% below its 10-year median of 99.92. GuruFocus rates KURA with a GF Score™ of 28/100. The stock has 7 warning signs investors should review. Among 732 Biotechnology companies, Kura Oncology ranks better than 98.22% on this metric.
The historical rank and industry rank for Kura Oncology's Gross Margin % or its related term are showing as below:
KURA'
s Gross Margin % Range Over the Past 10 Years
Min: 99.63 Med: 99.92 Max: 99.92
Current: 99.63
During the past 12 years, the highestGross Margin % of Kura Oncology was 99.92%. The lowest was 99.63%. And the median was 99.92%.
KURA's Gross Margin % is ranked better than 98.22% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs KURA: 99.63
Kura Oncology had a gross margin of 98.57% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Kura Oncology was 0.00% per year.
Kura Oncology (NAS:KURA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Kura Oncology had a gross margin of 98.57% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Kura Oncology Gross Margin % Related Terms
Kura Oncology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Kura Oncology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KURA vs REPL, AVTX, SANA: Gross Margin % Comparison
For the Biotechnology subindustry, Kura Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kura Oncology Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kura Oncology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Kura Oncology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Kura Oncology (KURA) has a Gross Margin % of 98.57% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Kura Oncology and its competitors. This is near median its historical median of 99.92. Over the past decade, Kura Oncology's Gross Margin % has ranged from 99.63 to 99.92. According to the industry distribution chart, Kura Oncology ranks #13 out of 732 companies in the Biotechnology industry, placing it in the top 1.8%.
Is Kura Oncology's Gross Margin % too high?
Kura Oncology's current Gross Margin % of 98.57% is near median its 10-year median of 99.92. Over the past 10 years, this metric has ranged from a low of 99.63 to a high of 99.92. The Biotechnology industry median Gross Margin % is 60.91. Kura Oncology's value of 98.57% is 61.8% above this industry median. Based on the distribution chart, Kura Oncology ranks #13 out of 732 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kura Oncology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Kura Oncology's Gross Margin % compare to REPL and AVTX?
According to the Biotechnology industry distribution chart, Kura Oncology ranks #13 out of 732 companies for Gross Margin %. This places Kura Oncology in the top 2% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Kura Oncology's value of 98.57% is 61.8% above this benchmark. Historically, Kura Oncology's own Gross Margin % has ranged from 99.63 to 99.92 over the past decade. While the company's 10-year median is 99.92 vs. the industry median of 60.91, Kura Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kura Oncology's current Gross Margin % of 98.57% is 61.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Kura Oncology and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kura Oncology's current Gross Margin % is 98.57%, which is near median its own 10-year median of 99.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kura Oncology stock overvalued right now?
Kura Oncology (KURA) has a current Gross Margin % of 98.57%. The current Gross Margin % is 98.57%, which is near median its 10-year median of 99.92 and 61.8% above the Biotechnology industry median of 60.91. Kura Oncology's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Kura Oncology (KURA), the current Gross Margin % is 98.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
28GF Score
Get the complete analysis for KURA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KURA has been successfully added to your 
